<DOC>
	<DOCNO>NCT02335489</DOCNO>
	<brief_summary>14-SMI-2013 post market , observational , questionnaire base study assess effectiveness commercially available Axium neurostimulator management neuropathic pain foot and/or lower limb</brief_summary>
	<brief_title>A Post Market Cohort Assess Performance Spinal Modulation Neurostimulator System Management Chronic Neuropathic Pain Foot and/or Lower Leg</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<criteria>1 . Subject least 18 year old 2 . Subject able willing comply followup schedule protocol 3 . Chronic , intractable pain foot and/or lower leg least 6 month 4 . Failed conservative treatment chronic pain include limited pharmacological therapy , physical therapy interventional pain procedure chronic pain 5 . Minimum baseline pain rating 60 mm Visual Analog Scale primary region pain 6 . Subject able provide write informed consent 1 . Female subject childbearing potential pregnant/nursing , plan become pregnant unwilling use approve birth control 2 . Escalating change pain condition within past month evidence investigator examination 3 . Subject corticosteroid therapy intend site stimulation within past 30 day 4 . Subject radiofrequency treatment intend target Dorsal Root Ganglion within past 3 month 5 . Subject currently active implantable device include implantable cardioverter defibrillator , pacemaker , spinal cord stimulator intrathecal drug pump 6 . Subject unable operate device 7 . Subjects indwell device may pose increase risk infection 8 . Subjects currently active infection 9 . Subject participate another clinical investigation within 30 day 10 . Subject coagulation disorder use anticoagulant , opinion investigator , preclude participation 11 . Subject diagnose cancer past 2 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>